Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Topoisomerase I in the Era of Precision Medicine

21 Jun 2019

Abstract excerpt

Irinotecan and topotecan have been widely used as anticancer drugs for the past 20 years. Because of their selectivity as topoisomerase I (TOP1) inhibitors that trap TOP1 cleavage complexes, camptothecins are also widely used to elucidate the DNA repair pathways associated with DNA-protein cross-links and replication stress. This review summarizes the basic molecular mechanisms of action of TOP1 inhibitors, their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical and Molecular Research
Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31227499
DOI: 10.1158/1078-0432.ccr-19-1089

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Topoisomerase I in the Era of Precision MedicinePMID 31227499Read ↗

The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectivesSemantic proximity Read ↗

Biology and Development of DNA-Targeted Drugs, Focusing on Synthetic Lethality, DNA Repair, and Epigenetic Modifications for Cancer: A ReviewSemantic proximity Read ↗

Targeting DNA damage repair precision medicine strategies in cancerSemantic proximity Read ↗

Advancing cancer therapy: new frontiers in targeting DNA damage responseSemantic proximity Read ↗

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer TherapySemantic proximity Read ↗

Recent Developments in Combination Chemotherapy for Colorectal and Breast Cancers with Topoisomerase InhibitorsSemantic proximity Read ↗

Clinical approaches to overcome PARP inhibitor resistanceSemantic proximity Read ↗

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targetsSemantic proximity Read ↗

A patent review of topoisomerase I inhibitors (2016–present)Semantic proximity Read ↗

Topoisomerases and cancer chemotherapy: recent advances and unanswered questionsSemantic proximity Read ↗

Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewSemantic proximity Read ↗

DNA damage response inhibitors in cancer therapy: Mechanisms, clinical development, and combination strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.